Published in Melanoma Res on August 01, 2005
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther (2010) 1.30
Immunotherapy of distant metastatic disease. Ann Oncol (2009) 0.96
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer (2006) 0.83
Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol (2013) 0.79
Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin Exp Metastasis (2007) 0.76
High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res (2005) 3.38
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res (2003) 3.21
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res (2006) 1.38
Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol (2008) 1.25
High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer (2002) 1.17
VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res (2009) 1.06
Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res (2004) 1.05
Diagnosis delay in Libyan female breast cancer. BMC Res Notes (2012) 1.05
MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest (2010) 1.04
A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res (2010) 1.03
Baseline psychosocial predictors of survival in localized melanoma. J Psychosom Res (2007) 0.98
Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck (2006) 0.96
Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma. Melanoma Res (2007) 0.93
Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival. Cytokine (2009) 0.90
Obesity and physical inactivity are related to impaired physical health of breast cancer survivors. Anticancer Res (2013) 0.89
Renal cell carcinoma MIB-1, Bax and Bcl-2 expression and prognosis. J Urol (2004) 0.89
A prognostic model and staging for metastatic uveal melanoma. Cancer (2003) 0.89
Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response. Oncology (2002) 0.88
Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in libya. J Cancer (2012) 0.87
Loss of E-cadherin expression predicts disease recurrence and shorter survival in colorectal carcinoma. APMIS (2012) 0.87
High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res (2013) 0.87
Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma. J Gastrointest Cancer (2009) 0.86
Cancer-specific social support received by newly diagnosed cancer patients: validating the new Structural-Functional Social Support Scale (SFSS) measurement tool. Support Care Cancer (2004) 0.86
Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma. Melanoma Res (2008) 0.86
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer (2002) 0.85
Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma. Tumour Biol (2012) 0.84
The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res (2006) 0.83
Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta Oncol (2010) 0.83
MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand J Gastroenterol (2007) 0.83
Previous pregnancy is a favourable prognostic factor in women with localised cutaneous melanoma. Acta Oncol (2012) 0.82
Detection of melanoma-derived cancer-testis antigen CT16 in patient sera by a novel immunoassay. Int J Cancer (2011) 0.82
Local and systemic oxidant/antioxidant status before and during lung cancer radiotherapy. Free Radic Res (2009) 0.82
General practitioners' attitudes and ethical decisions in end-of-life care after a year of interactive Internet-based training. J Cancer Educ (2002) 0.82
Exhaled pentane as a possible marker for survival and lipid peroxidation during radiotherapy for lung cancer--a pilot study. Free Radic Res (2009) 0.81
Preoperative radiotherapy modulates ezrin expression and its value as a predictive marker in patients with rectal cancer. Hum Pathol (2010) 0.81
Noncancer life stresses in newly diagnosed cancer. Support Care Cancer (2008) 0.81
A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer (2012) 0.80
Impact of radiotherapy and chemotherapy on biomarkers of oxidative DNA damage in lung cancer patients. Clin Biochem (2009) 0.79
Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases. Scand J Gastroenterol (2007) 0.79
Up-regulation of alpha-catenin is associated with increased lymph node involvement in colorectal cancer. World J Gastroenterol (2008) 0.79
Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res (2005) 0.79
Randomized, controlled trial of the effect of e-feedback on knowledge about radiotherapy of breast cancer patients in Finland. Nurs Health Sci (2014) 0.78
Nuclear size as prognostic determinant in stage II and stage III colorectal adenocarcinoma. Anticancer Res (2006) 0.78
Melanoma-associated cancer-testis antigen 16 (CT16) regulates the expression of apoptotic and antiapoptotic genes and promotes cell survival. PLoS One (2012) 0.78
NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Cancer Chemother Pharmacol (2010) 0.78
Children of parents with cancer: a collaborative project between a child psychiatry clinic and an adult oncology clinic. Clin Child Psychol Psychiatry (2007) 0.78
Prognostic significance of DNA image cytometry in Libyan breast cancer. Oncology (2012) 0.77
Impact of life events on survival of patients with localized melanoma. Psychother Psychosom (2012) 0.77
Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. Melanoma Res (2011) 0.76
Prognostic value of bcl-2 expression among women with breast cancer in Libya. Tumour Biol (2013) 0.76
Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. Oncol Rep (2008) 0.76
Long-term progression-free survival in metastatic uveal melanoma after chemoimmunotherapy and consolidation thermoablation. Acta Oncol (2009) 0.76
The expression and distribution of group IIA phospholipase A2 in human colorectal tumours. Virchows Arch (2010) 0.76
Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin Exp Metastasis (2007) 0.76
Genetic variation in platelet integrin alphabeta (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma. BJU Int (2006) 0.76
Main effects and interactions of carbonic anhydrase IX, hypoxia-inducible factor-1α, ezrin and glucose transporter-1 in multivariate analysis for disease outcome in rectal cancer. Anticancer Res (2012) 0.75
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. Cancer (2014) 0.75
Concurrent decline of several antioxidants and markers of oxidative stress during combination chemotherapy for small cell lung cancer. Clin Biochem (2009) 0.75
Internet knowledge expectations by radiotherapy patients. Cancer Nurs (2008) 0.75
Treatment of squamous cell carcinoma of the oral cavity, oropharynx and hypopharynx--an analysis of 174 patients in south western Finland. Acta Oncol (2003) 0.75
[Support and control of psychological stress as experienced by cancer patient]. Duodecim (2002) 0.75
[Sentinel lymph node biopsy in patients with cutaneous melanoma]. Duodecim (2002) 0.75
Attitudes to terminal patients' unorthodox therapy: Finnish doctors' responses to a case scenario. Support Care Cancer (2003) 0.75
Psychosocial outcomes of e-feedback of radiotherapy for breast cancer patients: a randomized controlled trial. Psychooncology (2014) 0.75
[Directions for allogenic stem cell transplants and how they reflect on the operation and results of the transfer center in Turku]. Duodecim (2005) 0.75
[Prognostic factors and improving treatment of cutaneous melanoma]. Duodecim (2004) 0.75
[Not Available]. Duodecim (2007) 0.75
Nuclear area is a prognostic determinant in advanced colorectal cancer. Anticancer Res (2005) 0.75
[Not Available]. Duodecim (2007) 0.75
No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer. Anticancer Res (2012) 0.75
[Not Available]. Duodecim (2006) 0.75
[Childhood and adolescent cancer was cured--how to support health in adulthood?]. Duodecim (2014) 0.75
Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis. Anticancer Res (2009) 0.75
[Anemia and radiotherapy]. Duodecim (2002) 0.75
[Not Available]. Duodecim (2006) 0.75
[Are immunological treatments beneficial for malignant melanoma of the skin?]. Duodecim (2010) 0.75
Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels. Cancer Immunol Immunother (2014) 0.75